INS and type 2 diabetes mellitus: As NMDAR antagonists, like dextromethorphan, have been shown to increase serum insulin and lower blood glucose in type 2 diabetes patients [24,25], the potential signaling roles of these d-AAs through the NMDARs in human islets in vivo are suggested.